Drugs
Aveo Oncology Renal Cell Carcinoma Drug OK’d
FDA has approved an Aveo Oncology NDA for Fotivda (tivozanib) for treating adults with relapsed or refractory advanced renal cell carcinoma (RCC) who have received two or more prior systemic therapies. The approval of the next-generation vascular endothelial growth factor tyrosine kinase inhibitor was based on data from the